Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.52 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.50 |
| ▸ | CPB2 | Q96IY4 | 7/20 | 0.47 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | PLG | P00747 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL181035 | 1.00 | GSR (0.52) | GSRRNPEPCPB2GABRR1FOLH1 | |
| SCHEMBL4735950 | 1.00 | GSR (0.52) | GSRRNPEPCPB2GABRR1FOLH1 | |
| Hydrochloric Acid SCHEMBL920512 | 0.98 | GSR (0.50) | GSRRNPEPCPB2GABRR1FOLH1 | |
| Hydrochloric Acid SCHEMBL28300269 | 0.98 | GSR (0.50) | GSRRNPEPCPB2GABRR1FOLH1 | |
| Acetic Acid SCHEMBL919117 | 0.96 | CPB2 (0.49) | GSRRNPEPCPB2GABRR1FOLH1 | |
| SCHEMBL25238647 | 0.94 | CPB2 (0.45) | GSRRNPEPCPB2GABRR1CYP2D6 | |
| SCHEMBL527672 | 0.94 | CPB2 (0.45) | GSRRNPEPCPB2GABRR1CYP2D6 | |
| SCHEMBL7323886 | 0.94 | CPB2 (0.45) | GSRRNPEPCPB2GABRR1CYP2D6 | |
| Ammonia Solution, Strong SCHEMBL27491588 | 0.92 | CPB2 (0.44) | GSRRNPEPCPB2GABRR1FOLH1 | |
| SCHEMBL546909 | 0.88 | GSR (0.42) | GSRRNPEPCPB2FOLH1F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1964 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4687996-A1 | ANTIBODY-DRUG CONJUGATES AND USES THEREOF | Sorrento Therapeutics, Inc. (US) | 2026-02-11 | — | — | EP | claimed |
| EP-4687997-A2 | ANTIBODY-DRUG CONJUGATES AND USES THEREOF | Sorrento Therapeutics, Inc. (US) | 2026-02-11 | — | — | EP | claimed |
| EP-4565282-A1 | IMMUNOSTIMULATORY ANTI-PD-L1-DRUG CONJUGATES | Seagen Inc. (US) | 2025-06-11 | — | — | EP | claimed |
| US-20250129115-A1 | Methods Detecting Tertiary Amines and Compositions Related Thereto | UNIV EMORY (US) | 2025-04-24 | — | — | US | claimed |
| WO-2025082461-A1 | POLYPEPTIDE, BIOACTIVE CONJUGATE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 优洛生物(上海)有限公司 | 2025-04-24 | — | — | WO | claimed |
| EP-4522221-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF NUCLEIC ACID THERAPEUTICS | Entrada Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | claimed |
| WO-2024211236-A2 | ANTIBODY-DRUG CONJUGATES AND USES THEREOF | SORRENTO THERAPEUTICS, INC. (US) | 2024-10-10 | — | — | WO | claimed |
| WO-2024211234-A1 | ANTIBODY-DRUG CONJUGATES AND USES THEREOF | SORRENTO THERAPEUTICS, INC. (US) | 2024-10-10 | — | — | WO | claimed |
| US-20240261422-A1 | ANTHRACYCLINE ANTIBODY CONJUGATES | SEAGEN INC (US) | 2024-08-08 | — | — | US | claimed |
| CN-114264767-B | Biomarkers for diabetes diagnosis and uses thereof | 上海脉示生物技术有限公司 | 2024-07-09 | — | — | CN | claimed |
| WO-2005024380-A9 | METHOD AND SYSTEM FOR ASSAYING TRANSFERASE ACTIVITY | GELLIBOLIAN ROBERT (US) | 2005-07-07 | — | — | WO | claimed |
| WO-2005024380-A2 | METHOD AND SYSTEM FOR ASSAYING TRANSFERASE ACTIVITY | GELLIBOLIAN ROBERT (US) | 2005-03-17 | — | — | WO | claimed |
| US-20040220264-A1 | Bioavailability and improved delivery of acidic pharmaceutical drugs | YU RUEY J | 2004-11-04 | — | — | US | claimed |
| WO-2004082628-A2 | IMPROVED BIOAVAILABILITY AND IMPROVED DELIVERY OF ACIDIC PHARMACEUTICAL DRUGS | YU RUEY J (US) | 2004-09-30 | — | — | WO | claimed |
| US-20030194373-A1 | Angiogenesis targeting molecules | BRACCO IMAGING SPA (IT) | 2003-10-16 | — | — | US | claimed |
| EP-1056773-A2 | ANGIOGENESIS TARGETING MOLECULES | RESOLUTION PHARMACEUTICALS INC. (CA) | 2000-12-06 | — | — | EP | claimed |
| WO-1999040947-A2 | ANGIOGENESIS TARGETING MOLECULES | RESOLUTION PHARMACEUTICALS INC. (CA) | 1999-08-19 | — | — | WO | claimed |
| EP-0091237-B1 | DETERGENT COMPOSITION | AJINOMOTO CO., INC. (JP) | 1986-01-08 | — | — | EP | claimed |
| US-4447356-A | CYCLIC POLYPEPTIDES; MOLLUSC VENOMS; ANTICHOLINERGIC AGENTS; NERVOUS SYSTEM DISORDERS | OLIVERA BALDOMERO M | 1984-05-08 | — | — | US | claimed |
| EP-0091237-A1 | Detergent composition | AJINOMOTO CO., INC. (JP) | 1983-10-12 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129115-A1 | Methods Detecting Tertiary Amines and Compositions Related Thereto | DOT1L, SETDB1, PRMT3 | GSR 4431/4885RNPEP 744/4885CPB2 3499/4885 |
| US-20030194373-A1 | Angiogenesis targeting molecules | FLT1, FLT4, VEGFA | GSR 4323/4885RNPEP 54/4885CPB2 394/4885 |
| US-20240261422-A1 | ANTHRACYCLINE ANTIBODY CONJUGATES | BCR, TOP2A, ABCB1 | GSR 2786/4885RNPEP 1041/4885CPB2 3287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.